Literature DB >> 25156

Diseases and drug protein binding.

J P Tillement, F Lhoste, J F Giudicelli.   

Abstract

In a number of pathological states a decrease in the plasma protein binding of drugs is observed. This may be due to many factors related either to the protein, or the ligand (drug), or to the binding conditions. The most important of these disease states quantitatively are probably hypoalbuminaemia, conditions resulting in modification of the albumin compartment volume and the presence on albumin binding sites of pathological inhibitors of drug binding. A decrease in the extent of drug plasma protein binding does not necessarily lead to enhanced drug effects and therefore raises two important therapeutic questions. Firstly, does reduced protein binding have a clinically significant influence on the pharmacological effects of the drug? Secondly, if it does, is it preferable to modify the dosage regimen of the drug or to correct the plasma protein concentration prior to the administration of the drug? At present, only tentative answers can be given.

Mesh:

Substances:

Year:  1978        PMID: 25156     DOI: 10.2165/00003088-197803020-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  49 in total

1.  beta-Lipoproteins: possible plasma transport proteins for basic drugs.

Authors:  J J Vallner; L Chen
Journal:  J Pharm Sci       Date:  1977-03       Impact factor: 3.534

2.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

3.  Influence of free fatty acid concentration on drug binding to plasma albumin.

Authors:  A A Spector; E C Santos; J D Ashbrook; J E Fletcher
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

4.  Effect of injury on albumin synthesis in the rabbit.

Authors:  F C Ballantyne; W J Tilstone; A Fleck
Journal:  Br J Exp Pathol       Date:  1973-08

Review 5.  Drug protein binding and the nephrotic syndrome.

Authors:  R Gugler; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Fluid volume and albumin kinetics occurring with major surgery.

Authors:  R C Hoye; S H Bennett; G W Geelhoed; C Gorschboth
Journal:  JAMA       Date:  1972-12-04       Impact factor: 56.272

Review 7.  Renal failure, drug pharmacokinetics and drug action.

Authors:  J Fabre; L Balant
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 8.  Pathophysiological and disease-induced changes in drug distribution volume: pharmacokinetic implications.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 9.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

10.  Influence of long-chain free fatty acids on the binding of waraarin to bovine serum albumin.

Authors:  S Chakrabarti; R Laliberté; J Brodeur
Journal:  Biochem Pharmacol       Date:  1976-11-15       Impact factor: 5.858

View more
  45 in total

Review 1.  Clinical role of protein binding of quinolones.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 3.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 4.  The role of the protein-binding on the mode of drug action as well the interactions with other drugs.

Authors:  Christine Tesseromatis; Anastasia Alevizou
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Oct-Dec       Impact factor: 2.441

Review 5.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 6.  Pharmacokinetics of continuous renal replacement therapy.

Authors:  M Schetz; P Ferdinande; G Van den Berghe; C Verwaest; P Lauwers
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

7.  Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.

Authors:  H Echizen; S Saima; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

8.  Clinical Pharmacokinetics of indomethacin.

Authors:  L Helleberg
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

9.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

10.  Plasma protein binding of azapropazone in patients with kidney and liver disease.

Authors:  E Jähnchen; K J Blanck; K H Breuing; H J Gilfrich; T Meinertz; D Trenk
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.